Evaluation of a novel accommodating silicone IOL design: pilocarpine and cyclopentolate induced effect 20 months after implantation

Session Details

Session Title: Pseudophakic IOLs: Monofocal/Accommodative

Session Date/Time: Tuesday 13/09/2016 | 16:30-18:00

Paper Time: 17:30

Venue: Hall C2

First Author: : N.Hirnschall AUSTRIA

Co Author(s): :    R. Henson   J. Vincencio   A. Angeles   O. Findl   A. Phillips        

Abstract Details

Purpose:

To investigate a novel concept of an accommodating 1-piece silicone IOL.

Setting:

Manila, Philippines

Methods:

Each patient received a study IOL (Actalens™, Emmetrope, La Canada, CA) in one eye and a control IOL (CrystaLens® AO, B&L, USA, or a Acrysof IQ®, Alcon, USA) in the contra-lateral eye to allow for intra-individual comparison. At the 20months follow-up, two measurement days were set to measure all eyes before and after instilling 2% pilocarpine on the first day and 1% cyclopentolate and the second measurement day using an optical biometry device (Lenstar, Haag-Streit AG, Switzerland), respectively. PCO was graded by two examiners independently at the slit lamp.

Results:

In total, 16 eyes of 8 patients were included. In the study group and the control group the pilocarpine induced ACD shift was 0.32mm (SD: 0.12), (p=0.014) and 0.04mm (SD: 0.16), (p=0.854), respectively. In the study group and the control group, the mean cyclopentolate induced ACD shift was 0.14 (SD: 0.06) (p=0.014) and 0.03mm (SD: 0.03), (p=0.181), respectively. PCO and Nd:YAG rates were higher in the study group, but differences were not found to be significant (Acrysof vs Actalens p=0.100 and CrystaLens vs Actalens p= 0.174).

Conclusions:

The investigated IOL is a novel concept for an accommodating IOL and results showed a moderate pilocarpine induced forward shift of the IOL. Additionally, the investigated IOL seems to have a higher PCO rate compared to standard monofocal IOLs.

Financial Disclosure:

... gains financially from product or procedure presented